HomeStocks
FTT
Director Trades
| Date | Director | Value |
|---|
Company News
Biotechnology
Factor Therapeutics halts development of VF001 after failed drug trial, company restructures
Australian biomedical company Factor Therapeutics (ASX: FTT) will cease development of its VF001 drug for the treatment of chronic venous leg ulcers after a Phase 2 trial failed to prove the drug will improve healing in patients. The “disappointing results” released by the company this morning showed that use of the drug across a group […]
Biotechnology
Factor Therapeutics completes treatment for Phase 2 clinical trial on venous leg ulcers
Australian biomedical company Factor Therapeutics (ASX: FTT) is expecting “top line results” following the completion of a lengthy Phase 2 clinical trial of its VF001 drug for the treatment of venous leg ulcers. Based in the United States, the trial – which recorded its “first patient in” milestone in December 2016 – aimed to define […]
Company Videos
No videos found.